ProCE Banner Activity

Ixazomib Plus Cyclo/Dex in Newly Diagnosed MM

Slideset Download
Conference Coverage
First all-oral proteasome inhibitor–based combination showed promising efficacy and manageable toxicity in untreated MM.

Released: December 08, 2015

Expiration: December 06, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen